JP2022548104A - ピリジン窒素酸化物及びその製造方法と使用 - Google Patents
ピリジン窒素酸化物及びその製造方法と使用 Download PDFInfo
- Publication number
- JP2022548104A JP2022548104A JP2022516434A JP2022516434A JP2022548104A JP 2022548104 A JP2022548104 A JP 2022548104A JP 2022516434 A JP2022516434 A JP 2022516434A JP 2022516434 A JP2022516434 A JP 2022516434A JP 2022548104 A JP2022548104 A JP 2022548104A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- membered heterocycloalkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910863718 | 2019-09-12 | ||
| CN201910863718.6 | 2019-09-12 | ||
| CN201911094782.9 | 2019-11-11 | ||
| CN201911094782 | 2019-11-11 | ||
| CN202010531381.1 | 2020-06-11 | ||
| CN202010531381 | 2020-06-11 | ||
| CN202010923311.0 | 2020-09-04 | ||
| CN202010923311 | 2020-09-04 | ||
| PCT/CN2020/114700 WO2021047622A1 (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022548104A true JP2022548104A (ja) | 2022-11-16 |
| JP2022548104A5 JP2022548104A5 (https=) | 2023-09-27 |
Family
ID=74866555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516434A Pending JP2022548104A (ja) | 2019-09-12 | 2020-09-11 | ピリジン窒素酸化物及びその製造方法と使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230303495A9 (https=) |
| EP (1) | EP4043437A4 (https=) |
| JP (1) | JP2022548104A (https=) |
| KR (1) | KR20220101606A (https=) |
| CN (3) | CN118146148A (https=) |
| AU (1) | AU2020346951A1 (https=) |
| BR (1) | BR112022004495A8 (https=) |
| CA (1) | CA3150400A1 (https=) |
| CL (1) | CL2022000619A1 (https=) |
| CO (1) | CO2022004594A2 (https=) |
| GE (2) | GEP20247688B (https=) |
| MX (1) | MX2022003032A (https=) |
| PE (1) | PE20221515A1 (https=) |
| PH (1) | PH12022550584A1 (https=) |
| TW (1) | TWI770607B (https=) |
| WO (1) | WO2021047622A1 (https=) |
| ZA (1) | ZA202204100B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116829539B (zh) * | 2021-03-11 | 2025-11-25 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物晶型及其应用 |
| HRP20260068T1 (hr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| CN116891432A (zh) * | 2022-04-02 | 2023-10-17 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2023232117A1 (zh) | 2022-06-02 | 2023-12-07 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物的制备方法 |
| AU2023287273A1 (en) * | 2022-06-22 | 2025-01-09 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Nav1.8 inhibitor |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2024153856A1 (en) * | 2023-01-18 | 2024-07-25 | Orion Corporation | Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide |
| CN121419965A (zh) * | 2023-06-14 | 2026-01-27 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物的盐型、共晶及其制备方法和应用 |
| TW202500551A (zh) * | 2023-06-14 | 2025-01-01 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物與富馬酸的共晶體及其組合物、用途和製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025124502A1 (zh) * | 2023-12-13 | 2025-06-19 | 武汉人福创新药物研发中心有限公司 | 一种Nav1.8抑制剂化合物及其盐、多晶型和用途 |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011500599A (ja) * | 2007-10-11 | 2011-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なアミド |
| JP2011500600A (ja) * | 2007-10-11 | 2011-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なアリールアミド |
| JP2016506963A (ja) * | 2013-01-31 | 2016-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2016506964A (ja) * | 2013-01-31 | 2016-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのキノリンおよびキナゾリンアミド |
| JP2016508500A (ja) * | 2013-01-31 | 2016-03-22 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのアミド |
| JP2017504591A (ja) * | 2013-12-13 | 2017-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ |
| WO2019014352A1 (en) * | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| MX295245B (es) * | 2005-06-21 | 2012-01-26 | Mitsui Chemicals Inc | Derivado de amida e insecticida que contiene el mismo. |
| EP2004596A2 (en) * | 2006-04-11 | 2008-12-24 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| JP2010047480A (ja) * | 2006-12-19 | 2010-03-04 | Mitsui Chemicals Inc | 虫害の予防方法 |
| EP2655330B1 (en) * | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substituted pyridines as sodium channel blockers |
| CA3105657A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
-
2020
- 2020-09-11 BR BR112022004495A patent/BR112022004495A8/pt unknown
- 2020-09-11 AU AU2020346951A patent/AU2020346951A1/en not_active Abandoned
- 2020-09-11 GE GEAP202015928A patent/GEP20247688B/en unknown
- 2020-09-11 CN CN202410255352.5A patent/CN118146148A/zh active Pending
- 2020-09-11 PE PE2022000407A patent/PE20221515A1/es unknown
- 2020-09-11 TW TW109131318A patent/TWI770607B/zh active
- 2020-09-11 CN CN202080037787.2A patent/CN113906013B/zh active Active
- 2020-09-11 WO PCT/CN2020/114700 patent/WO2021047622A1/zh not_active Ceased
- 2020-09-11 PH PH1/2022/550584A patent/PH12022550584A1/en unknown
- 2020-09-11 US US17/642,020 patent/US20230303495A9/en not_active Abandoned
- 2020-09-11 JP JP2022516434A patent/JP2022548104A/ja active Pending
- 2020-09-11 GE GEAP202415928A patent/GEAP202415928A/en unknown
- 2020-09-11 CA CA3150400A patent/CA3150400A1/en active Pending
- 2020-09-11 EP EP20863934.4A patent/EP4043437A4/en active Pending
- 2020-09-11 CN CN202010957957.0A patent/CN112479996B/zh active Active
- 2020-09-11 MX MX2022003032A patent/MX2022003032A/es unknown
- 2020-09-11 KR KR1020227012157A patent/KR20220101606A/ko not_active Ceased
-
2022
- 2022-03-11 CL CL2022000619A patent/CL2022000619A1/es unknown
- 2022-04-11 ZA ZA2022/04100A patent/ZA202204100B/en unknown
- 2022-04-11 CO CONC2022/0004594A patent/CO2022004594A2/es unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011500599A (ja) * | 2007-10-11 | 2011-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なアミド |
| JP2011500600A (ja) * | 2007-10-11 | 2011-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なアリールアミド |
| JP2016506963A (ja) * | 2013-01-31 | 2016-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのピリドンアミド |
| JP2016506964A (ja) * | 2013-01-31 | 2016-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのキノリンおよびキナゾリンアミド |
| JP2016508500A (ja) * | 2013-01-31 | 2016-03-22 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのアミド |
| JP2017504591A (ja) * | 2013-12-13 | 2017-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ |
| WO2019014352A1 (en) * | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4043437A1 (en) | 2022-08-17 |
| BR112022004495A2 (pt) | 2022-05-31 |
| US20230026907A1 (en) | 2023-01-26 |
| PE20221515A1 (es) | 2022-10-04 |
| CN113906013B (zh) | 2024-03-12 |
| GEP20247688B (en) | 2024-11-11 |
| MX2022003032A (es) | 2022-07-12 |
| EP4043437A4 (en) | 2023-10-04 |
| CN112479996B (zh) | 2023-05-26 |
| BR112022004495A8 (pt) | 2023-04-18 |
| AU2020346951A1 (en) | 2022-04-28 |
| CN112479996A (zh) | 2021-03-12 |
| CN113906013A (zh) | 2022-01-07 |
| KR20220101606A (ko) | 2022-07-19 |
| TWI770607B (zh) | 2022-07-11 |
| WO2021047622A1 (zh) | 2021-03-18 |
| PH12022550584A1 (en) | 2024-03-04 |
| GEAP202415928A (en) | 2024-07-10 |
| CL2022000619A1 (es) | 2022-10-28 |
| CN118146148A (zh) | 2024-06-07 |
| CO2022004594A2 (es) | 2022-07-08 |
| US20230303495A9 (en) | 2023-09-28 |
| ZA202204100B (en) | 2024-04-24 |
| CA3150400A1 (en) | 2021-03-18 |
| TW202114990A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548104A (ja) | ピリジン窒素酸化物及びその製造方法と使用 | |
| JP2022548104A5 (https=) | ||
| CN112225695B (zh) | 一种氮氧化合物及其制备方法和用途 | |
| CN112457294B (zh) | 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途 | |
| WO2022235859A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| US20210188808A1 (en) | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | |
| US10604502B2 (en) | Substituted 5-cyanoindole compounds and uses thereof | |
| WO2020117626A1 (en) | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels | |
| BR112016008133B1 (pt) | amino-heteroaril benzamidas como inibidores de quinase, seus usos, e composição farmacêutica | |
| JP2011529952A (ja) | ジアザインドール誘導体およびｃ−ＪｕｎＮ末端キナーゼの阻害におけるそれらの使用 | |
| CA3211820A1 (en) | Isoquinolone compound and use thereof | |
| EP3724196B9 (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| JP5763673B2 (ja) | ｍＧｌｕＲ５受容体のアロステリック調節因子としての二環式チアゾール | |
| TWI879050B (zh) | 一系列含氮橋雜環化合物及其製備方法 | |
| TW202304864A (zh) | 1,3-取代的環丁基衍生物及其用途 | |
| KR20220106778A (ko) | 간 x 수용체 작용제로서의 1,2,4-옥사디아졸 유도체 | |
| CN113272315B (zh) | 一类类固醇化合物及其用途 | |
| HK40061625A (en) | Pyridine oxynitride, preparation method therefor and use thereof | |
| HK40061625B (zh) | 吡啶氮氧化合物及其制备方法和用途 | |
| JP2025537242A (ja) | 含窒素スピロ環式化合物、医薬組成物及びその用途 | |
| AU2023289121A1 (en) | Modulators of g protein-coupled receptor 88 | |
| AU2023287668A1 (en) | Modulators of g protein-coupled receptor 88 | |
| TW202444709A (zh) | 短肽類化合物及其製備方法和醫藥應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230908 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20230915 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240827 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250226 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20250526 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250526 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250617 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251209 |